{"id":"gtp-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Nephrotoxicity"}]},"_chembl":{"chemblId":"CHEMBL406375","moleculeType":"Small molecule","molecularWeight":"234.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GTP is a combination chemotherapy regimen where gemcitabine acts as an antimetabolite, docetaxel functions as a microtubule stabilizer, and cisplatin acts as an alkylating agent. Together, these three agents target cancer cells through complementary mechanisms to enhance cytotoxic effects.","oneSentence":"GTP is a chemotherapy regimen combining gemcitabine, docetaxel, and cisplatin to inhibit cancer cell proliferation through multiple mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:40.782Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT06136741","phase":"PHASE2","title":"A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nektar Therapeutics","startDate":"2023-11-15","conditions":"Moderate to Severe Atopic Dermatitis","enrollment":396},{"nctId":"NCT04942067","phase":"PHASE1, PHASE2","title":"APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-12-23","conditions":"Multiple Myeloma, Amyloidosis","enrollment":108},{"nctId":"NCT06038422","phase":"PHASE3","title":"GTP Regimen in the Treatment of Refractory/Recurrent HLH","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2023-09-15","conditions":"Refractory, Recurrence, Hemophagocytic Lymphohistiocytosis","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":132,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GTP regimen","genericName":"GTP regimen","companyName":"Beijing Friendship Hospital","companyId":"beijing-friendship-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GTP is a chemotherapy regimen combining gemcitabine, docetaxel, and cisplatin to inhibit cancer cell proliferation through multiple mechanisms. Used for Gastric cancer (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}